The influence of mianserin on TNF-α, IL-6 and IL-10 serum levels in rats under chronic mild stress

Manikowska, K.; Mikołajczyk, Monika; Mikołajczak, Przemysław Ł.; Bobkiewicz-Kozlowska, T.

doi:10.1016/j.pharep.2013.06.003

Cited by 32 publications

(28 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study does not confirm the data showing that the levels of IL-6 in patients with depressive disorders are higher than in healthy individuals [5][6][7][8][9][10][11]. The results obtained in our study also differ from the observations of researchers who believe that treatment with mianserin [28], amitriptyline [31] and SSRI [13] reduces the concentration of TNF-α in patients with depression, compared to its pre-treatment values .…”

Section: Resultscontrasting

confidence: 99%

“…It was demonstrated in an animal model study that administration of mianserin to rats with experimentally induced depression resulted in a significant reduction in the concentrations of IL-6 and TNF-α [28]. Służewska et al [29] observed reduced concentrations of IL-6 in depressed patients undergoing treatment with fluoxetine compared to pretreatment values.…”

Section: Introductionmentioning

confidence: 99%

“…Numerous contemporary studies show that antidepressive treatment has an effect on the concentration of proinflammatory cytokines [27,28]. It was demonstrated in an animal model study that administration of mianserin to rats with experimentally induced depression resulted in a significant reduction in the concentrations of IL-6 and TNF-α [28].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in the levels of kynurenic acid and selected proinflammatory cytokines after pharmacological treatment and electroconvulsive therapy (ECT) in patients with depressive disorder

Olajossy

Potembska

Skoczeń

et al. 2016

Current Problems of Psychiatry

View full text Add to dashboard Cite

The aim of the present study was to compare the concentrations of KYNA, 3-OH-KYN and the cytokines TNF-α and IL-6 in patients with depression vs. healthy controls as well as in patients with depression treated pharmacologically vs. those treated using ECT. We also evaluated the relationship between the concentrations of KYNA, 3-OH-KYN and the cytokines TNF-α and IL-6 and clinical improvement measured on the MADRS scale in patients treated pharmacologically and those treated with ECT.Subjects and methods: The study group comprised 29 patients aged 28 to 60 years with a diagnosis of a major depressive episode. Eleven of the patients received pharmacological treatment and 18 were treated with ECT.Patients were assayed for serum levels of KYNA and the cytokines IL-6 and TNF-α. Clinical improvement was measured on the MADRS depression rating scale and the clinical global impression (CGI) scale.Results: Significant differences were found in KYNA levels between depressive patients and healthy controls. Pharmacological treatment significantly contributed to the increase in KYNA levels and ECT – to the increase in TNF-α levels in depressive patients.Conclusions: Depressive patients have significantly lower concentrations of KYNA than healthy individualsDepressive patients who have undergone pharmacological treatment have significantly higher KYNA concentrations than before treatment.Depressive patients who have undergone ECT treatment have significantly lower TNF-α concentrations than before treatment.High pre-treatment levels of IL-6 are associated with a lower MADRS improvement index in pharmacologically treated patients with depression.

show abstract

Section: Resultscontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in the levels of kynurenic acid and selected proinflammatory cytokines after pharmacological treatment and electroconvulsive therapy (ECT) in patients with depressive disorder

Olajossy

Potembska

Skoczeń

et al. 2016

Current Problems of Psychiatry

View full text Add to dashboard Cite

show abstract

“…Among the multiple neurochemical changes that occur in response to stress, excessive inflammation processes is thought to play a major role in stressinduced cognitive impairments. Several studies have reported that exposure to stress increased the hippocampal [9,34,51] and plasma TNF-␣ levels [52]. Accumulating evidence indeed supports a relationship between inflammatory cytokines and various types of learning and memory.…”

Section: Discussionmentioning

confidence: 96%

TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression

Şahin

Karson

Balcı

et al. 2015

Behavioural Brain Research

103

View full text Add to dashboard Cite

“…One study has shown a decrease in TNF-α levels with selective serotonin re-uptake inhibitors treatment [19] . One preclinical study has shown that mianserin treatment resulted in a significant lowering of TNF-α in the blood of rats in an experimental model of depression [29] .…”

Section: Discussionmentioning

confidence: 99%

Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression

Gupta

Gupta²,

Tripathi³

et al. 2016

Pharmacology

View full text Add to dashboard Cite

Background: This study evaluated the clinical efficacy of mirtazapine and its effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-α (TNF-α) levels in patients of major-depressive disorder (MDD) with severe depression. Methods: Patients (aged 18-60) with MDD diagnosed by DSM-IV criteria, and Hamilton Rating Scale for Depression (HAM-D) score ≥25 were included (n = 30). Mirtazapine was given in the doses of 30 mg/day. All patients were followed up for 12 weeks for the evaluation of clinical efficacy, safety along with serum BDNF and TNF-α levels. Results: HAM-D score at the start of treatment was 30.1 ± 1.92, which significantly (p < 0.05) reduced to 13.47 ± 1.77 at 12 weeks of treatment. In responders, mean serum BDNF levels at the start of treatment were 2.32 ± 0.3 ng/ml, which significantly (p < 0.05) increased to 2.79 ± 0.33 ng/ml at 12 weeks of treatment and mean serum TNF-α levels at the start were 5.18 ± 0.67 pg/ml, which significantly decreased to 4.36 ± 0.72 pg/ml (p < 0.05) at 12 weeks of treatment. Conclusion: Our results suggest that mirtazapine is effective and well tolerated in severely depressed patients and treatment response is associated with an increase in serum BDNF and a decrease in serum TNF-α levels.

show abstract

The influence of mianserin on TNF-α, IL-6 and IL-10 serum levels in rats under chronic mild stress

Cited by 32 publications

References 41 publications

Changes in the levels of kynurenic acid and selected proinflammatory cytokines after pharmacological treatment and electroconvulsive therapy (ECT) in patients with depressive disorder

Changes in the levels of kynurenic acid and selected proinflammatory cytokines after pharmacological treatment and electroconvulsive therapy (ECT) in patients with depressive disorder

TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression

Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression

Contact Info

Product

Resources

About